시장보고서
상품코드
1593520

암 모노클로널 항체 시장 규모, 점유율, 성장 분석(유형별, 용도별, 최종사용자별, 지역별) : 산업 예측(2024-2031년)

Cancer Monoclonal Antibodies Market Size, Share, Growth Analysis, By Type (Human, Chimeric), By Application (Blood Cancer, Breast Cancer), By End-user (Hospitals, Research Institutes), By Region - Industry Forecast 2024-2031

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 211 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 암 모노클로널 항체 시장 규모는 2022년에 739억 달러로 평가되며, 2023년 875억 달러에서 2031년에는 3,379억 2,000만 달러로 확대하며, 예측 기간 중(2024-2031년) 18.40%의 CAGR로 성장할 전망입니다.

모노클로널 항체(mAb) 치료는 화학요법, 방사선 치료, 수술과 같은 기존 치료법을 보완하는 암 치료의 중요한 요소라는 인식이 확산되고 있습니다. 지난 20년 동안 mAb는 고형암과 혈액암 모두에서 매우 효과적인 치료법으로 자리 잡으며 암 발병률 증가와 강력한 신약 승인 파이프라인을 촉진했습니다. 현재 및 향후 승인될 예정인 mAb 치료제는 기존 화학요법에 비해 부작용이 상대적으로 적다는 치료적 이점이 있으며, 전 세계 수백만 명의 환자들에게 혜택을 줄 수 있는 잠재력을 가지고 있습니다. 저렴한 가격의 바이오시밀러 모노클로널 항체가 의료진에 의해 더 많이 수용되면서 예측 기간 중 시장 성장이 더욱 가속화될 것으로 예상됩니다. 그러나 COVID-19는 암 검진 수검률에 부정적인 영향을 미쳤으며, 2020년 4월 유방암 검진 수검률은 이전과 비교하여 87%나 급감했습니다. 이러한 감소는 치료의 상당한 지연을 초래하여 필요한 항암제에 대한 적시 접근, 질병 재발 및 치료 지연에 대한 우려를 불러일으키고 있습니다. 암은 여전히 억제되지 않는 세포 증식을 특징으로 하는 주요 만성질환으로, 암 발병률 증가는 앞으로도 mAb 치료제에 대한 수요를 주도하며 시장 확대를 견인할 것으로 보입니다. 전반적으로 암 치료제 시장 중 mAb 분야는 혁신적인 암 치료제에 대한 니즈와 팬데믹 이후 의료 접근성의 발전으로 인해 성장할 수 있는 여건이 조성되고 있습니다.

목차

서론

  • 분석 목적
  • 정의
  • 시장 범위

분석 방법

  • 정보 조달
  • 2차 데이터 소스와 1차 데이터 소스
  • 시장 규모 예측
  • 시장의 상정과 제한

개요

  • 시장 개요와 전망
  • 수급 동향 분석
  • 부문별 기회 분석

시장 역학과 전망

  • 시장 역학
    • 촉진요인
    • 기회
    • 억제요인
    • 과제
  • Porter의 산업 분석

주요 시장 인사이트

  • 기술 분석
  • 밸류체인 분석
  • 시장의 에코시스템
  • 사례 연구 분석
  • 규제 상황
  • 혁신 매트릭스
  • 주요 투자 분석
  • 주요 성공 요인
  • 경쟁의 정도

암 모노클로널 항체 시장 : 유형별

  • 시장 개요
  • 인간화
  • 인간
  • 키메라

암 모노클로널 항체 시장 : 용도별

  • 시장 개요
  • 혈액암
  • 유방암
  • 폐암
  • 악성 흑색종
  • 대장암
  • 간암
  • 기타

암 모노클로널 항체 시장 : 최종사용자별

  • 시장 개요
  • 병원
  • 연구기관
  • 기타

암 모노클로널 항체 시장 : 지역별

  • 시장 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 이탈리아
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카(MEA)
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 상위 5사의 비교
  • 주요 기업의 시장 포지셔닝(2023년)
  • 주요 시장 기업이 채택한 전략
  • 시장에서의 최근 활동
  • 주요 기업의 시장 점유율(2023년)

주요 기업 개요

  • AbbVie Inc.(미국)
  • Amgen Inc.(미국)
  • Merck & Co., Inc.(미국)
  • Bristol-Myers Squibb Company(미국)
  • Gilead Sciences, Inc.(미국)
  • Takeda Pharmaceutical Company(일본)
  • AstraZeneca plc(영국)
  • Eli Lilly and Company(미국)
  • Regeneron Pharmaceuticals, Inc.(미국)
  • BeiGene, Ltd(중국)
  • Biogen Inc.(미국)
  • Recordati Industria Chimica e Farmaceutica S.p.A(이탈리아)
  • Pfizer(미국)
  • Spectrum Pharmaceuticals, Inc.(미국)
  • Iovance Biotherapeutics, Inc.(미국)
  • Exelixis, Inc.(미국)
  • OncoOne(미국)
  • CureVac AG(독일)
  • Cellerant Therapeutics, Inc.(미국)
  • Celltrion, Inc.(한국)
  • Faron Pharmaceuticals Ltd.(핀란드)
KSA 24.12.02

Global Cancer Monoclonal Antibodies Market size was valued at USD 73.9 billion in 2022 and is poised to grow from USD 87.5 billion in 2023 to USD 337.92 billion by 2031, growing at a CAGR of 18.40% during the forecast period (2024-2031).

Monoclonal antibody (mAb) therapies are increasingly recognized as crucial components in the cancer treatment landscape, complementing traditional modalities such as chemotherapy, radiation, and surgery. Over the past two decades, mAbs have established themselves as highly effective treatments for both solid tumors and hematologic malignancies, spurred by rising cancer incidence rates and a robust pipeline of new drug approvals. Current and forthcoming mAb therapies hold the potential to benefit millions globally, offering a therapeutic advantage due to their relatively lower side effects compared to conventional chemotherapy. The growing acceptance of affordable biosimilar monoclonal antibodies by healthcare providers is expected to further enhance market growth in the forecast period. However, the COVID-19 pandemic has negatively impacted cancer screening rates, with a dramatic 87% drop observed in breast cancer screenings in April 2020 compared to previous years. This decline resulted in significant treatment delays, raising concerns about timely access to necessary cancer medications, disease recurrence, and the postponement of therapies. As cancer remains a major chronic disease characterized by unchecked cell proliferation, the escalating incidence of cancer cases will likely continue to drive demand for mAb therapies and bolster market expansion in the coming years. Overall, the mAb segment of the oncology market stands poised for growth, fueled by both the need for innovative cancer treatments and the evolution of healthcare access in a post-pandemic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Monoclonal Antibodies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Monoclonal Antibodies Market Segmental Analysis

Global Cancer Monoclonal Antibodies Market is segmented by Type, Application, End-user, end user and region. Based on Type, the market is segmented into Humanized, Human, Chimeric, and Murine. Based on Application, the market is segmented into Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, and Others. Based on End-user, the market is segmented into Hospitals, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is significantly driven by the alarming rise in cancer prevalence worldwide, which underscores the urgent need for innovative and effective treatment options. Monoclonal antibodies are favored over traditional therapies due to their ability to selectively target malignant cells, thereby improving treatment efficacy and minimizing adverse effects. As patient demand for advanced therapeutic solutions escalates, the market is further bolstered by increased investments in research and development aimed at discovering novel monoclonal antibody-based therapies. Furthermore, heightened awareness surrounding cancer leads to earlier detection and treatment initiation, propelling growth and development within this vital sector of oncology.

Restraints in the Global Cancer Monoclonal Antibodies Market

A significant market restraint for the global cancer monoclonal antibodies market is the prohibitively high cost associated with monoclonal antibody therapies. The advanced manufacturing processes and extensive research and development required for these therapies contribute to their steep pricing. This financial burden limits patient access, particularly among low-income communities and in countries with strained healthcare budgets. As a result, the expensive nature of these treatments may render them unaffordable for many, leading to increased out-of-pocket expenses and further hindering market growth and accessibility. This economic barrier could ultimately restrict the adoption of these potentially life-saving therapies across diverse populations.

Market Trends of the Global Cancer Monoclonal Antibodies Market

The Global Cancer Monoclonal Antibodies market is witnessing a significant trend towards the integration of combination therapies, reflecting an evolving landscape in oncology treatment. By leveraging monoclonal antibodies in conjunction with immunotherapies, targeted therapies, and chemotherapy, healthcare providers aim to combat cancer on multiple fronts, enhancing treatment efficacy while minimizing resistance. The synergistic effects observed, particularly with immune checkpoint inhibitors paired with monoclonal antibodies, underscore the potential for improved patient outcomes through deeper immune responses against tumors. This trend not only highlights the complexity of cancer but also emphasizes the shift towards personalized medicine, offering tailored and potent treatment options for diverse patient profiles.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Case study Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Cancer Monoclonal Antibodies Market by Type

  • Market Overview
  • Humanized
  • Human
  • Chimeric
  • Murine

Cancer Monoclonal Antibodies Market by Application

  • Market Overview
  • Blood Cancer
  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Liver Cancer
  • Others

Cancer Monoclonal Antibodies Market by End-user

  • Market Overview
  • Hospitals
  • Research Institutes
  • Others

Cancer Monoclonal Antibodies Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BeiGene, Ltd (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biogen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Recordati Industria Chimica e Farmaceutica S.p.A (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Spectrum Pharmaceuticals, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Iovance Biotherapeutics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Exelixis, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • OncoOne (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CureVac AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cellerant Therapeutics, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celltrion, Inc. (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Faron Pharmaceuticals Ltd. (Finland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제